salers and manufacturers further against the river. Individual physicians had the complete therapeutic freedom to prescribe to for each pharmaceutical product, which attached they kept, again under occasional clashes of interests. Patients either filled the index at the pharmacy or did not do not, dependent on their budgets. Usually patients did not have information about relative prices of these drugs at the different pharmacies in their sales markets and about the usefulness of the spare products, let alone on the profitability of the rivaling products, by which the relative costs become meant for the use, which is obtained with the drugs. Actually even until today, such crucial information is not generally accessible to the American patients. Pharmaceutical main leaders can have regarded this arrangement as correctly more working „free market “in addition. Again however no respecting economist could perhaps confirm it as even approximate value to a market, which meets the conditions of the first optimal condition theorem. Only with the spreading thirdparty of the payment in the 90's in the United States it gave a degree effective market energy on the demand side of the US-pharmaceutical market. Markets for pharmaceutical products world-wide are less than well balanced. The markets, those by monopsonistic to be controlled (particular customer) the power of the government to be able unfounded power over the offer side of the market to exercise and prices to the dynamically ineffective levels low pressure. At the other extreme become markets with wrongly informed and usually a weak demand side, which controls weakened further bymoral danger, which is associated in from third source payment the health, excessively from the offer side. Which is needed instead of, are evenly balanced marketswith from the energy, in which both sides of the market exactly over the prices, which are informed clinical effectiveness and the profitability of the rivaling products, which are offered for sale. Such markets to create is one of the main challenges, which confront health care politics manufacturers around the ball. This refers two facets also. First where patients enjoy now fully or nearly full insurance cover for use up-requiring medicines, are they probably to be asked to accept a larger portion of the costs of medicamentous therapy if, in order to only direct their understanding toward the relative „profitability “of the rivaling products. Secondly however both patients and their physicians to permit to appear as preisbewusstere buyers that use up-requiring medicines an information infrastructure emerges or should emerge, the possible users of the pharmaceutical products provided with objective, science based information on the prices can and relative profitability of the rivaling pharmaceutical products, which are offered in the market. Markets for pharmaceutical products worldwide acres less than wave balanced. Markets dominated by the monopsonistic (single more buyer) power OF government CAN exercise undue power more over the supply side OF the market and depress prices ton dynamically inefficient levels. RK the more other extreme, markets with ill informed and typically feeble that and side, weakened bymoral hazard inherent in health third party payment on, acres unduly dominated by the supply side. What is needed instead acres marketswith more evenly balanced OF power, into which both sides OF the market acres accurately informed about the prices, clinical effectiveness, and cost effectiveness OF the rival products being off-talks for sale. Creating look for markets is one OF the major challenges confronting health care policy makers around the globe. This wants involve two facets. Roofridge, where patients now enjoy full or nearly full insurance coverage for prescription drugs, they acres likely tons of fuel element asked ton assume A more larger flocks OF the cost OF drug therapy, if only tons of focus their minds on the relative “cost effectiveness” OF rival products. Second, more however, tons allow both patients and their physicians tons of act as more cost conscious purchasers OF prescription drugs, at information infrastructure wants emerge, or should emerge, that CAN provide potential users OF pharmaceutical products with objective, science based information on the prices and relative cost effectiveness OF rival pharmaceutical products being off-talks into the market. ]]>